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Abstract
In this chapter, we attempt to analyze the evolution of the amyloid-L (AL) molecular structure from its inception as part of
the AL precursor protein to its release by the secretases and its extrusion from membrane into an aqueous environment.
Biophysical studies suggest that the AL peptide sustains a series of transitions from a molecule rich in K-helix to a molecule in
which L-strands prevail. It is proposed that initially the extended C-termini of two opposing AL dimers form an antiparallel
L-sheet and that the subsequent addition of dimers generates a helical AL protofilament. Two or more protofilaments create
a strand in which the hydrophobic core of the L-sheets is shielded from the aqueous environment by the N-terminal polar
domains of the AL dimers. Once the nucleation has occurred, the AL filament grows in length by the addition of dimers or
tetramers. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The brains of patients with Alzheimer disease
(AD) are characterized by the presence of large de-
posits of extracellular ¢brillar amyloid-L (AL) pep-
tide in neuritic plaques and in the walls of cortical
and leptomeningeal vessels. The 10^12 nm diameter
amyloid ¢brils result from the polymerization of the
40^42 amino acids long AL peptide. The AL mole-
cules are derived from the 695 amino acids long type-
I transmembrane protein, known as AL precursor
protein (ALPP), by the action of the L- and Q-secre-
tases [1]. The AL is very reactive at physiological pH
since it contains seven positive and seven negative
charges, mostly localized at the N-terminal region
of the molecule. The AL peptide also contains two
hydrophobic domains comprising residues 17^21 and
residues 29^40/42, this latter sequence corresponds to
12^14 amino acids of the 24 residues putatively rep-
resenting the transmembrane domain of ALPP [1]. A
third proteolytic enzyme, the K-secretase, cleaves the
ALPP at residue 612, using the ALPP695 numbering.
When this cleavage occurs in combination with the
Q-secretase, the resulting peptide, AL residues 17^40/
42, is apparently non-toxic [2], non-¢brillar and
mostly con¢ned to di¡use deposits scattered through-
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out the neuropil [3,4]. Several studies have demon-
strated that the AL isolated from the neuritic plaque
cores is extensively truncated at the N-terminus,
probably resulting from the proteolytic action of
amino-peptidases [5^7]. This degradation is also ob-
served, although to a lesser degree, in the amyloid of
the cerebro-vascular deposits [8]. As a long-lived
molecule, the AL peptide accumulates a series of
post-translational modi¢cations such as isomeriza-
tion of Asp-1 and Asp-7 [7,8], racemization of Asp-
1, Asp-7, Asp-23 and Ser-8 [7,9,10], cyclization of
Glu-3 and Glu-11 [11^13] and oxidation of Met-35
[5,14]. These modi¢cations render the AL ¢brils more
stable, insoluble and resistant to proteolytic degrada-
tion [14,15]. For reasons still unclear, most of the AL
present in the ¢brillar deposits of the neuritic plaque
cores corresponds to the AL42 type, while the paren-
chymal and leptomeningeal vascular deposits have a
higher proportion of the more soluble AL40 [7,8,16^
20]. Interestingly, the amount of AL40 is excessively
accumulated in the cerebral vasculature of those in-
dividuals with AD carrying the apolipoprotein (Apo)
E genotype O4/O4 [21^24].
Until recently, the ¢brillar AL40/42 was considered
to be the only toxic form of this peptide [25,26]. The
profuse deposition of ¢brillar AL in the neuritic pla-
ques of the cerebral cortex appears to be associated
with dystrophic neurites [27]. Surrounding the spher-
ical cores of amyloid reactive microglia and astro-
cytes appear to participate in the production of ¢-
brillar AL and in the insulation of this material from
the rest of the neuropil [28]. The discovery of a pool
of soluble amyloid in AD brains and in cultured cells
triggered a reassessment of the role of monomeric/
dimeric and oligomeric AL in the pathology of this
dementia [29^32]. Damage to neurons may be caused
by intracellular and, to a lesser extent, extracellular
highly reactive and toxic AL dimers and oligomers
that can easily di¡use inside the cells and throughout
the narrow and convoluted extracellular space of the
brain. As a mechanism of defense against this per-
turbation, the glial cells apparently participate in the
e⁄cient uptake of obnoxious soluble extracellular AL
and in the ‘dumping’ of this material at localized
sites where the AL is concentrated. Soluble AL40/42
appears to be universal in physiological £uids such as
cerebrospinal £uid, plasma and urine of AD and
normal individuals [29,33^36].
In this chapter, we attempt to analyze the evolu-
tion of the AL molecular structure from its initial
inception as part of the ALPP to its release by the
secretases and its extrusion from the membrane into
an aqueous environment. Biophysical studies suggest
that the AL peptide sustains a series of transitions
from a molecule rich in K-helices to a molecule in
which L-sheets prevail. It has been proposed that
dimerization and oligomerization generate a nucleus
prompting the creation of stable ¢laments to shield
hydrophobic domains and overall to reduce entropy.
2. The initial membrane^AL topology
To understand the process of ALPP proteolysis by
the K-, L- and Q-secretases and the ensuing release of
the short (AL17^42) and the long (AL1^40/42) AL
peptides, it is necessary to investigate the conforma-
tional relationships between these domains and the
membrane. The actions of the K- and L-secretases on
the ALPP molecule may be in£uenced by the local
membrane environment which in turn is dictated by
the lipid composition of the bilayer. Among these
molecules, the well-regulated amount of cholesterol
inserted in the membranes appears to largely contrib-
ute to the thickness and £uidity of these structures
[37,38]. Di¡erent membranes, whether cytoplasmic,
endoplasmic, Golgi, mitochondrial, lysosomal, con-
tain variable quantities of cholesterol and other lipids
intimately linked to their speci¢c functions [39,40].
The length of hydrophobic transmembrane domains
of proteins residing in di¡erent organelles correlates
with their cholesterol content [39,41]. In addition,
specialized sub-domains within membranes, such as
caveolae and rafts, are also likely to in£uence the
function and structural association between mem-
brane and intrinsic proteins [42^44]. Di¡erences in
cholesterol concentration in di¡erent membranes
are su⁄cient to regulate transmembrane insertion
and membrane protein folding [45,46]. The role of
cholesterol in ALPP processing was recently under-
lined by the observation that in tissue culture, the
addition or depletion of this lipid results in signi¢-
cant variations in the production of AL or processing
of the ALPP [47^50]. This relationship between
ALPP, AL and cholesterol may be relevant to AD
since amounts of total brain cholesterol have also
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been found to be altered in AD when compared to
controls [51^53].
As an initial attempt to model the possible topo-
graphical relationships between membrane and the
AL peptide, a fragment of the amyloid precursor
protein (ALPP fragment: 312^42) was selected:
This peptide, containing the AL sequence 1^42
plus 12 additional amino acid residues immediately
adjacent to the N-terminus, was modeled and in-
serted into a lipid monolayer paradigm. The molec-
ular modeling software QUANTA, version 98.1111
(Molecular Simulations Inc., San Diego, CA, USA)
was used for molecular constructions and energy
minimizations. The force ¢eld parameters of
CHARMm version 25 [54] were used in the calcula-
tion. The three-dimensional structure of this frag-
ment was determined by secondary structure predic-
tion methods using the MPSSP secondary structure
module within the Biology Workbench [55]. The con-
sensus structure indicated a propensity for K-helices
comprising residues: 37^5, 10^22 and 29^42, with
turns in between (see Figs. 1 and 2). The ALPP frag-
ment was manually inserted in a hydrated lipid 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine
monolayer, derived from the bilayer model devel-
oped by Heller et al. [56]. The procedure of building
the protein^lipid complex involved deleting one lipid
molecule from the monolayer model, and inserting
the hydrophobic C-terminal K-helix residues 29^42
into the membrane cavity. The molecular structure
was energy-minimized using the Adopted-Basis New-
ton^Raphson algorithm until the rms force was be-
low 0.1 kcal/mol/Aî . The compositional structure is
shown in Figs. 1 and 2. The ¢gures were produced
using the program VMD [57].
Fig. 1. Molecular modeling of the ALPP fragment (corresponding to the AL sequence of residues 312^42) inserted in a lipid mem-
brane monolayer. (A) Side view. (B) Top view. The peptide is represented as a blue ribbon and the solvating water oxygens are de-
picted as red spheres. The phosphorus and nitrogen atoms of the lipid molecules are drawn as yellow and blue spheres, respectively.
The long hydrocarbon chains of the lipids are represented in green. This structure will be used in a future study as the starting point
for molecular dynamics simulations at room temperature. These simulations will address the important question of the relative angle
between the two surface K-helices, containing the K- and L-secretase sites and the possible modi¢cation of this angle upon insertion of
cholesterol in the membrane.
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The ALPP fragment^membrane monolayer model
is useful to investigate the disposition of lumenal K-
helices (residues 37^5 and 10^22) relative to the
membrane surface. The model suggests a corner (res-
idues 23^28) at the lumenal side of the transmem-
brane C-terminal sequence of residues 29^42, placing
the two N-terminal K-helices parallel to the mem-
brane surface. In addition, the existence of a second
loop at residues 6^9 positions the two N-terminal K-
helices in an energetically favorable antiparallel ori-
entation, thereby stabilizing their interactions. On
the membrane surface, some of the phosphate groups
and nitrogen atoms of the lipid molecules will be in
close proximity to interact with the positively
charged (32K, 5R, 6H, 13H, 14H and 16K) and
negatively charged (38E, 37E, 34E, 1D, 7D, 11E,
22E and 23D) groups of the ALPP fragment. Inter-
estingly, in this preliminary model, there is a close
proximity between lysyl 16 and aspartyl 1, the sites
of the K- and L-secretases, respectively. Moreover,
the O-amino group of the former appears to be ori-
ented towards the membrane surface whereas the
L-carboxyl of the latter has a more super¢cial orien-
tation (Fig. 2). Some studies have suggested that the
K-secretase cleavage of ALPP is not sequence speci¢c,
rather the distance from the surface of the adjacent
membrane, corresponding to 12 amino acids, appears
to be the determinant factor [58,59]. This interpreta-
tion does not necessarily mean a distance in terms of
Aî from the AL residue 28 to the AL residue 16, but
in all probability is related to the conformational
properties of the surrounding structures in relation
to the membrane surface. In synthesis, the angle of
orientation between the two K-helices relative to each
other and to the surface of the membrane would be
dictated by a complex ¢eld of non-polar and ionic
interactions. The thickness of the membrane will in-
£uence these interactions by modifying the position
of the transmembrane domain, and of the surface
helices relative to the interfacial environment. We
propose that thicker membranes, caused by the ad-
dition of cholesterol, will result a deeper penetration
of surface-located helices within the membrane inter-
face [60]. This shift in membrane^ALPP topology
may result in steric hindrance of the K-secretase site
and render the L-secretase site more accessible to
proteolysis and consequently to the increased pro-
duction of AL peptides.
The determination of the AL structure by nuclear
magnetic resonance (NMR) or by X-ray di¡raction
analysis in aqueous bu¡ers under physiological con-
ditions has been fraught with frustrations because of
the propensity of the AL peptides to aggregate. How-
ever, some valuable NMR structural information has
been obtained by dissolving the AL1^40 peptide in
40% tri£uoroethanol/water [61]. Under this condi-
tion, the secondary structure of AL reveals the con-
formation of a random coil and two helices compris-
ing the sequence of residues 15^23 and 31^35. More
recently, the NMR structure of AL1^40 was deter-
mined in a water^sodium dodecyl sulfate (SDS) mi-
celle medium which is analogous to a water^mem-
brane environment [62,63]. The peptide appears to be
unstructured and water-solvated between residues 1
and 14, followed by a long K-helical sequence from
residues 15 to 36, clearly solvated by the SDS, inter-
Fig. 2. Molecular modeling of the ALPP fragment (same model
as in Fig. 1) represented as a ribbon. Only lipids close to the
peptide are drawn in green color. (A) Side view. (B) Top view.
The positions of the acidic and basic amino acid residues are
shown in red and blue colors, respectively. Green and white de-
note the positions of polar and non-polar residues. In the mod-
el, the positions of the lysyl 16 and aspartyl 1 (blue and red
van der Waals spheres, respectively), the sites of the K- and L-
secretase postulated activity, are shown in close proximity, lying
along the antiparallel K-helices.
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rupted by a hinge around residues 25^27. With in-
creasing pH, in the water^SDS micelle environment
the AL1^40 undergoes a structural transition from K-
helix to random coil probably related to the depro-
tonation of residues 22E and 23D. In addition, the
accepted location of the transmembrane domain (res-
idues 29^52) has been challenged by Craik and col-
leagues who suggested the sequence of residues 25^46
instead [62]. This is an appealing concept since the
site of the Q-secretase has been suggested to be resi-
due AL46 [64] and is also the site of several ALPP
mutations (V46F, V46G and V46I) observed in fam-
ilial AD [65^67]. Shortening of the C-terminus of
AL1^46 to either residue 40 or residue 42 could be
e⁄ciently performed by carboxypeptidases.
The molecular structure of AL1^40 in water^SDS
micelle medium, with the methionyl at position 35
oxidized by hydrogen peroxide to yield methionyl
sulfoxide, was recently investigated by circular di-
chroism (CD) and NMR spectroscopy [63]. Under
these conditions, the AL peptide adopts a random
coil structure with one helical region comprising res-
idues 16^24. Other NMR studies performed at di¡er-
ent pHs and solvent conditions have also revealed a
helical structure around this sequence [61,68]. In Fig.
3, we recreated the three-dimensional structure of the
oxidized 35 methionyl AL1^40 as deposited in the
Protein Data Bank (1ba6). AL probably exists in a
dynamic £ux of di¡erent conformations, dependent
upon environmental conditions [69^71], interactions
with other molecules, and metal binding ability [72^
74]. The mostly unstructured molecule shown in Fig.
3 may represent a transitional conformation along
the accepted evolution of AL from K-helixCrandom
coilCL-sheet [75]. Interestingly, the stable K-helical
sequence of residues 16^24 (KLVFFAEDV) appar-
ently plays an important role in ¢brillogenesis. Sub-
stitutions in the hydrophobic sequence of residues
17^20 by polar amino acids decrease the L-sheet con-
tent in water and in the solid state [76]. Replacement
of any residue within the sequence of residues 17^23
by prolyl increases the solubility of AL and alters the
stability of the L-sheet inhibiting ¢lament formation
[77]. Furthermore, in three independent studies, ad-
dition of the synthetic peptides KLVFF (AL residues
16^20), or KLVFFAEDVG (AL residues 15^25) or
LPFFD (based on the AL sequence LVFF) to solu-
tions of freshly prepared synthetic AL partially in-
hibited ¢brillogenesis [78^80]. It is possible that the
basic building block of the AL ¢laments is the dimer-
Fig. 3. The structure of the AL1^40 peptide (35 methionyl sulfoxide) in water^SDS micelle medium obtained by NMR [63]. The only
K-helical segment comprising residues 16^24 is indicated by the blue rod. N and C indicate the N- and C-termini, respectively. The
amino acid residues side chain characteristics are identi¢ed by the same color code as given in Fig. 2.
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ic AL. We proposed in our previous model that the
hydrophobic sequence of residues 17^21 is pivotal in
the process of dimerization [81].
The soluble monomeric largely amphoteric and
amphipathic AL is very reactive with a very large
number of molecules as already demonstrated by
several laboratories [82^94]. The presence of free
AL in the brain and physiological £uids of non-de-
mented individuals suggests that either the AL levels
are too small to cause perturbations or alternatively,
the peptide exists in a non-toxic conformation or is
e⁄ciently cleared. The role of chaperone or carrier
molecules may be decisive in maintaining the latter
conditions.
3. From AL monomers to polymeric ¢brils:
experimental observations and models
The release of the AL peptide from its associated
membrane and ALPP results in its exposure to a
thermodynamically unfavorable aqueous medium
and to interactions with ions and multiple molecules
including another AL peptide. Recent data have re-
vealed the presence of stable soluble dimeric AL in
brain homogenates [95^97], cell culture media [98] as
well as in synthetic AL preparations [14,99,100].
Likewise, AL may readily associate with other nu-
merous molecules such as K1-antichymotrypsin
[85,86], albumin [89,90], Apo E [101,102], Apo J
[82,103], K2-macroglobulin [84,104], amyloid P com-
ponent [105,106], complement proteins [91,92], K-
synuclein [107,108], heparan sulfate proteoglycan
[87,109], receptor for advanced glycation end-prod-
ucts [93], endoplasmic reticulum AL binding protein
[94,110], just to name a few. In the ¢nal analysis, the
structural changes and molecular interactions experi-
enced by the AL peptide in the human brain, from
the moment of its membrane release to its ¢nal in-
corporation into the extracellular amyloid ¢laments,
still remain shrouded in mystery. Examination of the
AD cerebral cortex by electron microscopy demon-
strated that the extracellular amyloid deposits form
an array of V10 nm ¢laments of a variable length
[27,111]. In cross-section, the ¢laments appear to be
composed of a series of 5^6 electron dense symmetric
subunits peripherally disposed around an electron-
translucent core [112,113]. X-ray di¡raction analysis
of AL ¢laments revealed a predominant feature in
which there are meridional re£ections at 4.76 Aî
and equatorial re£ections at 10.6 Aî . These re£ections
suggested a model in which a series of antiparallel
cross-L pleated sheets are oriented parallel to the
main axis of the ¢lament, while the direction of the
constituent L-strands is perpendicular to the ¢bril
axis, making the hydrogen bonds between strands
parallel to the ¢bril axis [114,115].
Experiments with synthetic AL peptides showed
that lyophilized AL when dissolved in aqueous bu¡-
ers sustains a series of conformational transitions.
Infrared spectroscopy suggests that these changes
may be initiated by the generation of antiparallel
L-strands joined by a hairpin loop formed by resi-
dues 26^29 [116]. CD of AL dissolved in aqueous
bu¡ers indicates the presence of two populations in
terms of secondary structure: one with an extensive
random coil conformation and another with predom-
inant L-strands [75,117]. Short term incubation pro-
motes the transition of the latter species of AL into
¢lamentous structures [75]. Long term incubation of
synthetic AL1^42 results in the intra¢brillar genera-
tion of irreversibly denatured dimers and tetramers
that are highly resistant to proteolytic degradation
[14]. Furthermore, the irreversible oligomerization is
accelerated by the presence of aspartyl isomerizations
which are commonly observed in the AL isolated
from the amyloid cores of the neuritic plaques [14].
Molecular modeling has been used to predict the
three-dimensional structure of AL1^42 [81]. This
study was based on sequence homology, the thread-
ing algorithm TOPITS [118] and experimental obser-
vations derived from numerous biophysical obser-
vations. The structure of AL1^42 was optimally
superimposed on the K-carbon backbone of three
TOPITS hits represented by the lipid binding pro-
teins: 1ifb, 1pya and 1cid [81]. These three molecules
exhibited a common antiparallel L-structure with AL.
Because of their length and the torque imposed
by the hydrogen bonding, the initial antiparallel
L-strands may promote the generation of a Greek
key motif [119^121]. This structural motif displays
four antiparallel L-strands with corners formed by
the AL residues 7^8, 16^17, 25^28 and 37^38. In
order to shield unfavorable hydrophobic domains
from the aqueous media, the AL probably interacts
with another molecule to form a dimeric structure
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with the conformational characteristics of a L-barrel.
Abnormalities in side chain interactions and carbon
backbone exertions were relieved by means of molec-
ular dynamic simulations and energy minimizations.
The dimeric AL structure displays a hydrophobic
core surrounded by hydrophilic residues creating
shallow crevices into which the non-polar C-termini
are folded (Fig. 4A). The compact globular dimeric
AL1^42 structure measures V27 AîU32 Aî similar in
dimensions to the AL dimers isolated from the AD
brain (V35 Aî ) as measured by atomic force micros-
copy (AFM) which is shown in Fig. 4B [95]. The
dimeric AL model has the positive and negative
charges at the surface and exposes the sequence of
residues 13^16 (HHQK). This sequence is critical in
the interaction of AL with the heparan sulfate pro-
teoglycans on the surface of microglia eliciting in
these cells the ability to kill neurons [2,122]. The di-
merization of AL also creates a potential ¢eld for
zinc binding [72]. In general, the conformational fea-
tures of the N-terminal domains in the AL dimers
also agree with other physicochemical studies in
terms of AL topology, aggregation and toxicity
[87,123^127].
In the designed model, the hydrophobic C-termini
(residues 30^42) by virtue of being at the surface of
the dimeric structure have the ability of extending
and interacting with the equally extended C-termini
of an opposite dimer to create an antiparallel L-sheet
[81]. This structure, shown in Fig. 5A, was based on
the solid state NMR studies of Lansbury and col-
leagues in which the C-terminal sequence of residues
34^42 naturally produced an antiparallel stack of
L-strands [128]. The adjacent addition of these stacks
will create a ribbon-like helical structure, a proto¢la-
ment, similar to that described for the transthyretin
by Blake and Serpell [129]. The amphipathic and
amphoteric N-terminal domains of AL, comprising
residues 1^28, are localized at opposite sites interact-
ing with the N-termini of adjacent AL dimers. Dur-
ing the transition from dimer to proto¢lament, the
sequence of residues 17^23 re-localizes on the oppo-
site interfaces of the AL dimer potentially interacting
with supra- and infra-adjacent dimers. In terms of
energy, the proto¢lament is thermodynamically in
an unfavorable condition because the hydrophobic
L-sheet is exposed to the aqueous media. To over-
come this situation, two or three nascent proto¢la-
ments may associate side by side to create a nucleus
of an intertwined helical structure in which the non-
polar C-terminal sequences are shielded by the
mostly hydrophilic N-terminal domains of AL [81].
Fig. 4. A model and AFM of AL dimers. (A) A low energy
three-dimensional model of dimeric AL. A detailed description
of the physicochemical characteristics of the model is given in a
previous publication [81]. The amphipatic N-terminal regions
(residues 1^28) of each of the AL monomers are shown in red
and green space ¢lling display. Each of the hydrophobic C-ter-
minal domains, shown in yellow and blue licorice, folds into
shallow crevices formed by the mostly polar N-terminal regions.
The AL dimer generates a compact globular structure which
measures 27 Aî by 32 Aî . The arrows indicate the point at which
the C-terminus of one AL molecule interacts with the N-termi-
nus of the adjacent AL molecule. (B) AFM views of dimeric
AL isolated from the neuritic plaque cores of amyloid separated
by column chromatography. The arrows point to the dimeric
peptide which measured 35^38 Aî . The larger diameter of the
AFM dimer as against that of the theoretical model may be
due to the hydration shell around the human-derived material.
The molecular mass of AL dimers was con¢rmed by mass spec-
trometry and Western blot [95].
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A molecular model of two helical proto¢laments in-
terwined side by side is shown in Fig. 5B^E. Based
on transmission electron microscopy [130] and AFM
studies [95,131,132], two of these putative strands
may be further intertwined to generate an 8^10 nm
AL ¢lament similar to those observed in the AD
brain.
In an alternative model, the AL residues 14^23
have been proposed as the basic sequence in ¢bril
formation because of its capacity for generating anti-
parallel L-sheets with the same sequence of adjacent
AL molecules [133]. The hydrophobic C-terminal se-
quence of AL (residues 30^42) is proposed to form
an intramolecular L-sheet that folds over the core of
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residues 14^23. In this model, the N-terminal domain
of AL residues 1^13 was considered non-important in
the process of ¢brillogenesis since it is partially de-
graded in the neuritic plaque core amyloid. However,
partial degradation of the N-terminus is insigni¢cant
in vascular amyloid [7,8]. We believe that in AL ¢-
brillogenesis, as it occurs in the brain, the N-terminal
region of this peptide is essential to shield the C-
terminal hydrophobic core [81]. In all probability,
in the neuritic plaque amyloid deposits the N-termi-
nal degradation of AL occurs after the ¢bril is
forged.
Several experimental observations have demon-
strated the in vitro presence of AL proto¢lament in-
termediates [100]. By size exclusion chromatography,
synthetic AL1^40 dimers elute, after 24 h of incuba-
tion as a single fraction. A wide range of AL proto-
¢laments, measuring 6^10 nm in diameter and 5^160
nm in length, are eluted as a single fraction in the
void volume [100]. In this experiment, fully grown
AL ¢laments were sedimented by centrifugation prior
to the chromatographic step. Those remaining in the
supernatant too large to transit in the void volume of
the matrix are retained at the top of the column. We
would like to suggest that the proto¢laments frac-
tionated by column chromatography may represent
part of continuous distribution of actively growing
¢laments more than an intermediate and discrete
subclass of aggregates. If indeed the neurons are
the major source of AL in AD, then electron micros-
copy has failed to localize proto¢laments, in the
range of sizes observed in the chromatographic
void volume, either in the neuronal cytosol or organ-
elles.
The absence of intraneuronal proto¢laments and
¢laments suggests that in these cells, damage may be
done by soluble AL monomers/dimers or very small
oligomers. Soluble AL is a very reactive molecule due
to its ability to establish electrostatic and hydropho-
bic interactions. It is capable of rapidly binding to a
large number of molecules and membrane structures
causing serious alterations in cellular homeostasis,
and the neuron should not be an exception
[94,134^140]. The available evidence suggests a sce-
nario in which AL as soon as it is released from
ALPP and extruded from the membrane reacts with
other molecules hindering ¢brillogenesis. Following
secretion of AL complexes and uptake by glial cells,
the toxic soluble AL is ¢nally deposited in a localized
area. Fibrillogenesis may developed by a nucleation
dependent association and growth by the end-termi-
nal addition of AL to yield a helical ¢brillar polymer
[141]. It has been observed that deposition of AL
onto pre-existing templates of amyloid follows ¢rst-
order kinetics and is dependent on the AL concen-
tration with an optimum at physiological pH [142].
In addition, the narrow and intricate extracellular
space of the brain parenchyma ¢lled with extracellu-
lar matrix would hinder the di¡usion of proto¢la-
ments. It has been proposed that the glial electron-
translucent coated vesicles, putatively carrying non-
¢lamentous AL, fuse with the cell membrane to form
coated pits where the polymerization of amyloid ¢l-
aments is suggested to occur [143]. A similar situa-
tion has been observed in the transgenic human
ALPP mice [144]. A related phenomenon may take
place at the surface of the vascular tunica media
where soluble AL complexed to carrier molecules is
Fig. 5. Molecular models of AL dimers and proto¢laments. (A) Two AL dimers with extended C-termini forming an antiparallel
L-sheet stabilized by intermolecular hydrogen bonding and hydrophobic interactions. This model is based on the NMR studies of
Lansbury and colleagues [128]. The L-sheet is £anked by the N-terminal globular domains of the dimers (represented in red and blue
ribbons). The successive stacking of dimers creates a helical ribbon or proto¢lament. A model of a two-proto¢lament strand is shown
in ribbons and space ¢lling displays viewed in a normal to the ¢lament axis (B and C) and along the ¢lament axis (D and E), respec-
tively. Each proto¢lament resembles a helical ‘ladder’ in which each of the ‘railings’ is formed by the consecutive superimposition of
the N-terminal domains (residues 1^28) of AL dimers (shown in yellow and blue, and red and purple), and the ‘rungs’ formed by the
extended C-termini antiparallel L-strands (residues 30^42) of opposing AL dimers (depicted in white). Two proto¢laments intertwined
in parallel against each other generate a core of two helical L-sheets (white ribbons and balls) with their hydrogen bonds parallel to
the proto¢lament main axis. In this structure, the hydrophobic C-termini of the AL peptides are shielded from the aqueous environ-
ment by the mostly polar N-terminal AL residues. For simplicity, a strand made of two proto¢laments is shown. However, models
with strands of three [81] and four proto¢laments can also be generated. We suggest that, in vivo, the accretion of AL molecules at
the growing end of the ¢lament is in the form of either dimers or tetramers rather than by the lateral assembly of preformed proto¢-
laments. A is reproduced with permission from Oxford University Press [81].
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internalized by myocytes and subsequently deposited
along the extracellular space [145]. In both cases,
brain parenchyma and vascular walls, high concen-
trations of AL are secreted into de¢ned extracellular
microenvironments where ¢brillogenesis takes place.
The deposition of amyloid in the neuritic plaques by
glial cells may be very similar to the deposition of
procollagen into the cytoplasmic recesses of ¢bro-
blasts [146]. A recreation of AL oligomerization
and ¢brillogenesis in vitro probably have very little
resemblance to the oligomerization and ¢brillogene-
sis occurring in the highly complex environment of
the human brain. This is illustrated by the intimate
association of lipids, carbohydrates and proteins with
the amyloid ¢brils puri¢ed from the AD brain [147].
Based on high resolution electron microscopy, a
model of the neuritic plaque amyloid ¢laments has
recently been proposed by Kisilevsky and colleagues
[148]. In this paradigm, a core of amyloid P compo-
nent and chondroitin sulfate proteoglycan is sur-
rounded by a layer of heparan sulfate proteoglycan
onto which a peripheral coat of 1 nm AL ¢laments is
associated.
Fibrillar AL is beyond doubt a toxic and extrane-
ous material capable of triggering and sustaining a
subtle but chronic in£ammatory reaction [149] that
further contributes to the destruction of the neuropil.
However, a collection of polymerized AL at the cen-
ter of the neuritic plaque surrounded by glial cells
may be the most e⁄cient way of concealing, concen-
trating and immobilizing neurotoxic soluble AL. This
tenet is well-illustrated by our recent ¢nding that the
cortical soluble AL concentration is the best predic-
tor of synaptic change in the brain of AD patients
[150]. In addition, overexpression of mutant human
ALPP in neurons of transgenic mice causes a decline
in the density of presynaptic terminals and neurons
well before amyloid plaques appear [151]. Both of
these observations suggest that soluble AL, free or
in association with other molecules, is capable of
injuring the neurons. Finally, it would not be far-
fetched to suggest that in the absence of localized
¢brillar AL deposits, the widespread distribution of
toxic soluble AL may result in a shorter clinical evo-
lution of AD. In this context, we also suggest that
the cores of amyloid in the AD brain may represent
a mechanism of defense, which in the end also has
catastrophic consequences.
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